2013Middle East Journal of NursingRequires access

Chemotherapy Induced Nausea and Vomiting on Quality of Life among Cancer Patients : A Review

Ehssan Al-Abdallah, Nijmeh Al‐Atiyyat

Open publisher page 1 citations

Abstract

Introduction and Background Chemotherapy is considered the first drug of choice of physicians to treat cancer patients; between 500,000 and 1 million Americans receive chemotherapy each year. Nausea and vomiting affects 70 to 80 percent of people who receive chemotherapy and can result in significant morbidity ( Rudolph. Navari, 2007 ). First of all the classification of nausea and vomiting in patients receiving chemotherapy could be acute: i.e. occurring within 24 hours of chemotherapy; delayed, occurring between 24 hours and 5 days after treatment; breakthrough, occurring despite prophylactic treatment; anticipatory, occurring before chemotherapy treatment; and refractory, occurring during subsequent cycles when antiemetics have failed in earlier cycles; this effect varies from one patient to another according to chemotherapy type, doses, route and patient experience.

About this research paper

What this paper is about

Introduction and Background Chemotherapy is considered the first drug of choice of physicians to treat cancer patients; between 500,000 and 1 million Americans receive chemotherapy each year. Nausea and vomiting affects 70 to 80 percent of people who receive chemotherapy and can result in significant morbidity ( Rudolph. Navari, 2007 ). First of all the classification of nausea and vomiting in patients receiving chemotherapy could be acute: i.e. occurring within 24 hours of chemotherapy; delayed, occurring between 24 hours and 5 days after treatment; breakthrough, occurring despite prophylactic treatment; anticipatory, occurring before chemotherapy treatment; and refractory, occurring during subsequent cycles when antiemetics have failed in earlier cycles; this effect varies from one patient to another according to chemotherapy type, doses, route and patient experience.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Introduction and Background Chemotherapy is considered the first drug of choice of physicians to treat cancer patients; between 500,000 and 1 million Americans receive chemotherapy each year. Nausea and vomiting affects 70 to 80 percent of people who receive chemotherapy and can result in significant morbidity ( Rudolph. Navari, 2007 ). First of all the classification of nausea and vomiting in patients receiving chemotherapy could be acute: i.e. occurring within 24 hours of chemotherapy; delayed, occurring between 24 hours and 5 days after treatment; breakthrough, occurring despite prophylactic treatment; anticipatory, occurring before chemotherapy treatment; and refractory, occurring during subsequent cycles when antiemetics have failed in earlier cycles; this effect varies from one patient to another according to chemotherapy type, doses, route and patient experience.

Key concepts: Nausea, Vomiting, Chemotherapy, Medicine, Cancer, Refractory (planetary science), Chemotherapy-induced nausea and vomiting, Antiemetic

Related papers

Back to paper searchBrowse research topicsOriginal source
Chemotherapy Induced Nausea and Vomiting on Quality of Life among Cancer Patients : A Review — Research Paper | ScholarLens